Differences in TRAIL-induced changes of Mcl-1 expression among distinct human colon epithelial cell lines
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
19782681
DOI
10.1016/j.yexcr.2009.09.019
PII: S0014-4827(09)00409-1
Knihovny.cz E-resources
- MeSH
- Epithelial Cells metabolism MeSH
- Humans MeSH
- Neoplasm Metastasis pathology MeSH
- Cell Line, Tumor MeSH
- Colonic Neoplasms metabolism pathology MeSH
- Myeloid Cell Leukemia Sequence 1 Protein MeSH
- TNF-Related Apoptosis-Inducing Ligand physiology MeSH
- Proto-Oncogene Proteins c-bcl-2 genetics MeSH
- Gene Expression Regulation MeSH
- Cell Survival MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Myeloid Cell Leukemia Sequence 1 Protein MeSH
- TNF-Related Apoptosis-Inducing Ligand MeSH
- Proto-Oncogene Proteins c-bcl-2 MeSH
In addition to its ability to act as a promising inducer of tumor-specific cell death, TRAIL has also been shown to stimulate signaling pathways leading to cancer cell survival. We examined the changes of anti-apoptotic Mcl-1 protein level following TRAIL treatment of human cell lines representing different stages of colon carcinogenesis-adenocarcinoma (HT-29, HCT116) or secondary metastasis (SW620), together with cell line derived from human fetal colon (FHC). While TRAIL was capable of triggering an anti-apoptotic signaling leading to significant early ERK-mediated transcriptional up-regulation of Mcl-1 in selected colon adenocarcinoma cell lines, none or very limited effects were demonstrated in cell lines derived from colon lymph node metastasis or fetal colon, respectively. We demonstrated an immediate impact of Mcl-1 protein level manipulations on the course of early acute apoptotic response of colon adenocarcinoma cells to TRAIL. It is therefore essential to consider the dynamics of modulation of Mcl-1 level and the balance between TRAIL-induced pro- and anti-apoptotic pathways when predicting the response of cells in different stages of cancer development, and designing the anticancer therapy using TRAIL.
References provided by Crossref.org